verified SJR 1,645 · Q1 • database Scopus / SJR & Web of Science indexed

France · Springer Paris

workspace_premium Q1 — Oncology lock_open Open Access

Targeted Oncology

Targeted Oncology is a journal indexed in SJR in Oncology and Cancer Research with an H index of 63. It has a price of 3190 €. It has an SJR impact factor of 1,645 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,645.

ISSN: 1776-2596

Publisher: Springer Paris

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,645 Q1

H-index 63

Acceptance rate pie_chart

31%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.190 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,645

H-index

Docs (year)

Docs 3y

212

Total refs

3311

Cites 3y

850

Citable 3y

203

Cites/Doc 2y

3.26

Ref/Doc

37.63

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma

Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study

Diagnostic challenges of respiratory adverse events during everolimus treatment

Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase

Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases

Combining targeted therapies

Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer

Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment

SHOW MORE ARTICLES

Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?

A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer

c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis

Biological significance of myeloperoxidase (MPO) on green tea component, (-)-epigallocatechin-3-gallate (EGCG)-induced apoptosis: its therapeutic potential for myeloid leukemia

BI 853520, a FAK-Simile of Prior FAK Inhibitors?

Beyond outstanding results with VEGFR/PDGFR inhibitors in advanced hepatocellular carcinoma: can imaging help where biomarkers keep us waiting?

Author's Reply to Christelle de la Fouchardiere: "Regorafenib: Start Low and Go Slow"

Are we ready to move away from nature? The rapamycin story

Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7-11 October 2016

Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion

FAQs

Targeted Oncology has an SJR of 1,645 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3190 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Targeted Oncology is 31%.

Targeted Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Targeted Oncology?

What is the APC / publication cost?

What is the acceptance rate?